GlassScriptPhysician profile
Mindy J Byrd
NPI 1376858761
$7,561.91
in general payments reported to CMS, 2019-2025
24 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $894 · 2022: $1,298 · 2023: $1,215 · 2024: $3,153 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Travel and Lodging: $1,282 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,038.53 |
| Travel and Lodging | $1,282.04 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,864.52 | 2021-2025 | Linq II, Onyx Frontier, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $1,155.52 | 2021-2025 | |
| Abiomed | $741.16 | 2023-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.63 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $337.28 | 2022-2025 | Watchman Access System, Cds - Mct/Cem Monitoring, Patientcare Link |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.30 | 2021-2025 | Lifevest |
| Amgen INC. | $227.07 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $179.58 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $178.26 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $162.23 | 2021-2024 | Farxiga, Lokelma, Brilinta |
| Shockwave Medical, INC | $134.67 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $90.92 | 2022 | |
| Lilly USA, LLC | $75.01 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $63.75 | 2024 | Arcalyst |
| Novo Nordisk INC | $55.22 | 2024-2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.91 | 2024-2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $50.00 | 2025 | Amvuttra |
| Teleflex LLC | $43.45 | 2025 | Guideliner |
| Kestra Medical Technology Services, INC. | $38.49 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $36.67 | 2021-2022 | |
| Scpharmaceuticals INC. | $33.34 | 2023-2024 | |
| Pfizer INC. | $31.13 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $25.46 | 2022 | |
| Philips North America LLC | $22.34 | 2025 | Lm Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.